MX369039B - Vacuna contra el circovirus porcino tipo 2. - Google Patents

Vacuna contra el circovirus porcino tipo 2.

Info

Publication number
MX369039B
MX369039B MX2016007224A MX2016007224A MX369039B MX 369039 B MX369039 B MX 369039B MX 2016007224 A MX2016007224 A MX 2016007224A MX 2016007224 A MX2016007224 A MX 2016007224A MX 369039 B MX369039 B MX 369039B
Authority
MX
Mexico
Prior art keywords
virus type
circo virus
porcine circo
vaccine against
against porcine
Prior art date
Application number
MX2016007224A
Other languages
English (en)
Other versions
MX2016007224A (es
Inventor
Vicky Fachinger
Melanie Sno
Hendrik Witvliet Maarten
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49680926&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369039(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2016007224A publication Critical patent/MX2016007224A/es
Publication of MX369039B publication Critical patent/MX369039B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0241Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/105Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/10011Circoviridae
    • C12N2750/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una vacuna que comprende un inmunógeno que no se replica del circovirus porcino tipo 2 para usarse en el tratamiento profiláctico de un animal que tiene anticuerpos circulantes dirigidos contra el circovirus porcino tipo 2 contra una infección por el circovirus porcino tipo 2 patogénico por una sola dosis de administración de la vacuna en la dermis del animal.
MX2016007224A 2013-12-03 2014-12-02 Vacuna contra el circovirus porcino tipo 2. MX369039B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195515 2013-12-03
PCT/EP2014/076224 WO2015082458A1 (en) 2013-12-03 2014-12-02 Vaccine against porcine circo virus type 2

Publications (2)

Publication Number Publication Date
MX2016007224A MX2016007224A (es) 2016-07-21
MX369039B true MX369039B (es) 2019-10-25

Family

ID=49680926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007224A MX369039B (es) 2013-12-03 2014-12-02 Vacuna contra el circovirus porcino tipo 2.

Country Status (13)

Country Link
US (1) US10130698B2 (es)
EP (1) EP3076996B1 (es)
JP (1) JP6605469B2 (es)
KR (1) KR20160093047A (es)
CN (2) CN110354258A (es)
BR (1) BR112016012435A8 (es)
CA (1) CA2931137C (es)
DK (1) DK3076996T3 (es)
ES (1) ES2771899T3 (es)
MX (1) MX369039B (es)
PL (1) PL3076996T3 (es)
RU (1) RU2712155C2 (es)
WO (1) WO2015082458A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110354258A (zh) 2013-12-03 2019-10-22 英特维特国际股份有限公司 抗猪圆环病毒2型的疫苗
JP6906511B2 (ja) * 2015-10-22 2021-07-21 インターベット インターナショナル ベー. フェー. ローソニア・イントラセルラリス感染から生じる障害に対してmda陽性動物を防御するためのワクチン
EP3432920A1 (en) * 2016-03-23 2019-01-30 Intervet International B.V. A vaccine for intradermal application against pcv2 and prrs virus infection
EP3609533A1 (en) * 2017-04-13 2020-02-19 Intervet International B.V. Vaccines containing swine pathogens for associated non-mixed use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ322398A (en) 1995-11-30 2000-02-28 Pig Res & Dev Corp Vaccine compositions comprising non-pathogenic form of Lawsonia intracellularis, nucleic acid sequences thereof and treatment of intestinal disease
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
KR101146545B1 (ko) 2003-07-24 2012-07-05 메리얼 리미티드 수중유 에멀젼을 포함하는 백신 제형물
EP1709067B1 (en) 2004-01-22 2010-06-09 Intervet International BV Lawsonia intracellularis subunit vaccines
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US20080248061A1 (en) * 2005-09-09 2008-10-09 Intervet International B.V. Pcv-2 Vaccine
CN104383526B (zh) 2005-12-29 2018-09-18 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2免疫原性组合物用于减轻猪临床症状的用途
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP2094872B2 (en) 2006-12-15 2020-02-19 Boehringer Ingelheim Animal Health USA Inc. Treatment of anti-PCV2 antibody seropositive pigs with PCV2 antigen
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
EP2242511A4 (en) * 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌(Lawsonia intracellularis)、豬肺炎黴漿菌(Mycoplasma hyopneumoniae)及豬環狀病毒(Porcine circo virus)用疫苗
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌(Lawsonia intracellularis)用疫苗
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US10130699B2 (en) 2013-12-03 2018-11-20 Intervet Inc. Vaccine against Lawsonia intracellularis and porcine circovirus 2
CN110354258A (zh) 2013-12-03 2019-10-22 英特维特国际股份有限公司 抗猪圆环病毒2型的疫苗

Also Published As

Publication number Publication date
CN105848675A (zh) 2016-08-10
JP2017501984A (ja) 2017-01-19
EP3076996A1 (en) 2016-10-12
CN110354258A (zh) 2019-10-22
DK3076996T3 (en) 2020-03-09
US10130698B2 (en) 2018-11-20
PL3076996T3 (pl) 2020-05-18
ES2771899T3 (es) 2020-07-07
JP6605469B2 (ja) 2019-11-13
CA2931137C (en) 2023-03-14
BR112016012435A8 (pt) 2018-01-30
US20170157236A1 (en) 2017-06-08
CA2931137A1 (en) 2015-06-11
KR20160093047A (ko) 2016-08-05
RU2712155C2 (ru) 2020-01-24
EP3076996B1 (en) 2020-01-15
WO2015082458A1 (en) 2015-06-11
MX2016007224A (es) 2016-07-21
BR112016012435A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
PH12018500572A1 (en) Hepatitis b core protein modulators
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
MX2021015329A (es) Composiciones a base de nanoparticulas.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
BR112015022197A2 (pt) tratamento de cataplexia
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
MX2017006709A (es) Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales.
WO2016011324A3 (en) 5'-triphosphate oligoribonucleotides
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
PH12016500946A1 (en) Composition for preventing and curing mycoplasma infection
MX369039B (es) Vacuna contra el circovirus porcino tipo 2.
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2019003258A (es) Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.
MX2018000379A (es) Material no tejido tratado que tiene una afinidad por un ingrediente activo.
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MX2020006061A (es) Una vacuna para proteccion contra streptococcus suis.
AR099416A1 (es) Terapia combinada para la hipertensión resistente

Legal Events

Date Code Title Description
FG Grant or registration